Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101130839 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-9726 (Electronic) Linking ISSN: 14749718 NLM ISO Abbreviation: Aging Cell Subsets: MEDLINE

Publication: Oxford, UK : Wiley-Blackwell
Original Publication: Oxford, UK : Blackwell Pub., c2002-

Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/metabolism ; Glucagon-Like Peptide-1 Receptor*/agonists ; Hypoglycemic Agents*/therapeutic use; Humans ; Glucagon-Like Peptide 1/metabolism ; Longevity

To help ensure an expanded healthy lifespan for as many people as possible worldwide, there is a need to prevent or manage a number of prevalent chronic diseases directly and indirectly closely related to aging, including diabetes and obesity. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have proven beneficial in type 2 diabetes, are amongst the few medicines approved for weight management, and are also licensed for focused cardiovascular risk reduction. In addition, strong evidence suggests several other beneficial effects of the pleiotropic peptide hormone, including anti-inflammation. Consequently, GLP-1 RAs are now in advanced clinical development for the treatment of chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease and Alzheimer's disease. In sum, GLP-1 RAs are positioned as one of the pharmacotherapeutic options that can contribute to addressing the high unmet medical need characterising several prevalent aging-related diseases, potentially helping more people enjoy a prolonged healthy lifespan.
(© 2023 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd.)

J Gen Intern Med. 2019 Jun;34(6):944-951. (PMID: 30815788)
JAMA Intern Med. 2021 Apr 1;181(4):511-519. (PMID: 33555311)
JACC Basic Transl Sci. 2018 Nov 21;3(6):844-857. (PMID: 30623143)
Sci Rep. 2021 Sep 17;11(1):18522. (PMID: 34535716)
Brain. 2020 Oct 1;143(10):3067-3076. (PMID: 33011770)
Lancet Neurol. 2020 Jul;19(7):582-590. (PMID: 32562683)
Nat Rev Dis Primers. 2015 Jul 30;1:15018. (PMID: 27188921)
N Engl J Med. 2021 Mar 25;384(12):1113-1124. (PMID: 33185364)
J Clin Pharm Ther. 2020 Sep;45 Suppl 1:43-60. (PMID: 32910487)
Diabetes Care. 2011 Aug;34(8):1749-53. (PMID: 21636795)
Obesity (Silver Spring). 2022 Apr;30(4):802-840. (PMID: 35333446)
Front Endocrinol (Lausanne). 2019 May 03;10:266. (PMID: 31130916)
Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. (PMID: 34425083)
JAMA. 2021 Apr 13;325(14):1403-1413. (PMID: 33625476)
Ther Adv Endocrinol Metab. 2022 Jul 19;13:20420188221112490. (PMID: 35874312)
Sci Rep. 2021 Nov 11;11(1):22063. (PMID: 34764398)
Mol Metab. 2021 Apr;46:101102. (PMID: 33068776)
Lancet Diabetes Endocrinol. 2021 Sep;9(9):595-605. (PMID: 34358471)
Postgrad Med. 2022 Jan;134(sup1):5-17. (PMID: 36691309)
Nat Rev Cardiol. 2020 Mar;17(3):137-144. (PMID: 31406340)
J Epidemiol Glob Health. 2020 Mar;10(1):107-111. (PMID: 32175717)
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. (PMID: 28930295)
Clin Geriatr Med. 2008 Aug;24(3):395-405, v. (PMID: 18672179)
Curr Diabetes Rev. 2014;10(4):238-50. (PMID: 24998439)
N Engl J Med. 2022 Jul 21;387(3):205-216. (PMID: 35658024)
Biochim Biophys Acta Mol Basis Dis. 2017 May;1863(5):1078-1089. (PMID: 27567931)
Aging Cell. 2023 May;22(5):e13818. (PMID: 37191234)
J Hepatol. 2019 Oct;71(4):793-801. (PMID: 31279902)
Commun Biol. 2021 Jun 2;4(1):656. (PMID: 34079050)
Nat Commun. 2020 Sep 4;11(1):4413. (PMID: 32887883)
Biochem Biophys Res Commun. 2018 Jan 1;495(1):1034-1040. (PMID: 29175324)
Lancet. 2021 May 8;397(10286):1736-1748. (PMID: 33894838)
Mol Metab. 2019 Dec;30:72-130. (PMID: 31767182)
Lancet. 2017 Oct 7;390(10103):1664-1675. (PMID: 28781108)
Nat Med. 2018 Jul;24(7):931-938. (PMID: 29892066)
Alzheimers Dement (N Y). 2022 Feb 23;8(1):e12268. (PMID: 35229024)
Nat Rev Endocrinol. 2021 Sep;17(9):534-548. (PMID: 34172940)

Keywords: Alzheimer's disease; cardiovascular diseases; chronic kidney diseases; diabetes mellitus; glucagon-like peptide-1; healthy aging; non-alcoholic steatohepatitis; obesity

89750-14-1 (Glucagon-Like Peptide 1)
0 (Glucagon-Like Peptide-1 Receptor)
0 (Hypoglycemic Agents)

Date Created: 20230516 Date Completed: 20230517 Latest Revision: 20230627

20230628

PMC10186594

10.1111/acel.13818

37191234